The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial

Background: Currently, there is a paucity of pharmacological treatment options for posttraumatic stress disorder (PTSD), and the development of a novel pharmacotherapeutic approach has become a matter of great interest. Objective: We conducted a 12-week open-label clinical trial to examine the effic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of psychotraumatology 2021-01, Vol.12 (1), p.1859821-1859821
Hauptverfasser: Hori, Hiroaki, Itoh, Mariko, Matsui, Mie, Kamo, Toshiko, Saito, Takuya, Nishimatsu, Yoshiko, Kito, Satoshi, Kida, Satoshi, Kim, Yoshiharu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1859821
container_issue 1
container_start_page 1859821
container_title European journal of psychotraumatology
container_volume 12
creator Hori, Hiroaki
Itoh, Mariko
Matsui, Mie
Kamo, Toshiko
Saito, Takuya
Nishimatsu, Yoshiko
Kito, Satoshi
Kida, Satoshi
Kim, Yoshiharu
description Background: Currently, there is a paucity of pharmacological treatment options for posttraumatic stress disorder (PTSD), and the development of a novel pharmacotherapeutic approach has become a matter of great interest. Objective: We conducted a 12-week open-label clinical trial to examine the efficacy and safety of memantine, an N-methyl-D-aspartate receptor antagonist, in the treatment of civilian PTSD. Method: Thirteen adult patients with DSM-IV PTSD, all civilian women, were enrolled. They were monitored at an ambulatory care facility every week until 4 weeks and then every 4 weeks until 12 weeks. Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day and then titrated. Concomitant medications were essentially kept unchanged during the trial. The primary outcome was PTSD diagnosis and severity assessed with the Posttraumatic Diagnostic Scale (PDS). Results: Of the 13 cases, one dropped out and two were discarded due to the protocol deviation, and the analysis was done for the remaining 10. Mean PDS total scores decreased from 32.3 ± 9.7 at baseline to 12.2 ± 7.9 at endpoint, which was statistically significant with a large effect (paired t-test: p = .002, d = 1.35); intrusion, avoidance, hyperarousal symptoms were all significantly improved from baseline to endpoint. Six patients no longer fulfilled the diagnostic criteria of PTSD at endpoint. Some adverse, but not serious, effects possibly related to memantine were observed, including sleep problems, sleepiness, sedation, weight change and hypotension. Conclusions: Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated. Future randomized controlled trials are necessary to verify the efficacy and safety of memantine in the treatment of PTSD. * Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated.         * Its pre-post effect size is 1.35, almost comparable to that of trauma-focused CBT. * The finding accords with the results of recent studies of fear memory in rodents.
doi_str_mv 10.1080/20008198.2020.1859821
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_11c2e0de2c714176b9a33b52a7ca232e</doaj_id><sourcerecordid>2691935705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-a3885ef8d00dfc8c8e5479c7b16e00443f1576e90487588173d4c31997d07c3c3</originalsourceid><addsrcrecordid>eNp9klFrFDEQxxdRbKn9CMqCL75cnSS7m8QHUYrVQsGX-hzmsrNtjmxyJrnKfXtzvWtpfRACSWZ-889k-DfNWwZnDBR85ACgmFZnHHgNqV4rzl40x7v4QsEwvHxyPmpOc17VGwx1Kf26ORJiUCC64bhx17fU0jQ5i3bbxqmdacZQXKDWhbbUZEmEZaZQdlnr7px3GNp1zKUk3MxYnG1zhXJuR5djGil9aisR1xQWHpfkq4RD_6Z5NaHPdHrYT5pfF9-uz38srn5-vzz_erWwvRzKAoVSPU1qBBgnq6yivpPayiUbCKDrxMQqRxo6JXulmBRjZwXTWo4grbDipLnc644RV2ad3IxpayI6cx-I6cZgqk17MoxZTjASt5J1TA5LjUIse47SIhecqtbnvdZ6s5xptHUKCf0z0eeZ4G7NTbwzUslOC1kFPhwEUvy9oVzM7LIl7zFQ3GTDO60BWK9YRd__g67iJoU6KsMHzbToJfSV6veUTTHnRNNjMwzMzhvmwRtm5w1z8Eate_f0J49VD06owJc94MIU04x_YvKjKbj1MU0Jg3XZiP-_8ReDqMgx</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2691935705</pqid></control><display><type>article</type><title>The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial</title><source>DOAJ Directory of Open Access Journals</source><source>Co-Action Open Access Journals</source><source>PubMed Central Open Access</source><source>Access via Taylor &amp; Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hori, Hiroaki ; Itoh, Mariko ; Matsui, Mie ; Kamo, Toshiko ; Saito, Takuya ; Nishimatsu, Yoshiko ; Kito, Satoshi ; Kida, Satoshi ; Kim, Yoshiharu</creator><creatorcontrib>Hori, Hiroaki ; Itoh, Mariko ; Matsui, Mie ; Kamo, Toshiko ; Saito, Takuya ; Nishimatsu, Yoshiko ; Kito, Satoshi ; Kida, Satoshi ; Kim, Yoshiharu</creatorcontrib><description>Background: Currently, there is a paucity of pharmacological treatment options for posttraumatic stress disorder (PTSD), and the development of a novel pharmacotherapeutic approach has become a matter of great interest. Objective: We conducted a 12-week open-label clinical trial to examine the efficacy and safety of memantine, an N-methyl-D-aspartate receptor antagonist, in the treatment of civilian PTSD. Method: Thirteen adult patients with DSM-IV PTSD, all civilian women, were enrolled. They were monitored at an ambulatory care facility every week until 4 weeks and then every 4 weeks until 12 weeks. Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day and then titrated. Concomitant medications were essentially kept unchanged during the trial. The primary outcome was PTSD diagnosis and severity assessed with the Posttraumatic Diagnostic Scale (PDS). Results: Of the 13 cases, one dropped out and two were discarded due to the protocol deviation, and the analysis was done for the remaining 10. Mean PDS total scores decreased from 32.3 ± 9.7 at baseline to 12.2 ± 7.9 at endpoint, which was statistically significant with a large effect (paired t-test: p = .002, d = 1.35); intrusion, avoidance, hyperarousal symptoms were all significantly improved from baseline to endpoint. Six patients no longer fulfilled the diagnostic criteria of PTSD at endpoint. Some adverse, but not serious, effects possibly related to memantine were observed, including sleep problems, sleepiness, sedation, weight change and hypotension. Conclusions: Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated. Future randomized controlled trials are necessary to verify the efficacy and safety of memantine in the treatment of PTSD. * Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated.         * Its pre-post effect size is 1.35, almost comparable to that of trauma-focused CBT. * The finding accords with the results of recent studies of fear memory in rodents.</description><identifier>ISSN: 2000-8066</identifier><identifier>ISSN: 2000-8198</identifier><identifier>EISSN: 2000-8066</identifier><identifier>DOI: 10.1080/20008198.2020.1859821</identifier><identifier>PMID: 33680346</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Alzheimer's disease ; Ambulatory care ; Child &amp; adolescent psychiatry ; Clinical ; clinical trial ; Clinical trials ; Drug therapy ; efficacy ; Eficacia ; Ensayo Clínico ; FDA approval ; Health psychology ; Memantina ; memantine ; memoria ; Memory ; Mental health ; Neurogenesis ; Post traumatic stress disorder ; Posttraumatic stress disorder (PTSD) ; Psychotherapy ; re-experiencing ; Reexperimentación ; safety ; Seguridad ; Trastorno de Estrés Postraumático (TEPT) ; 创伤后应激障碍 (PTSD); 美金刚; 记忆; 临床试验; 再体验; 有效性; 安全性</subject><ispartof>European journal of psychotraumatology, 2021-01, Vol.12 (1), p.1859821-1859821</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2021</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c576t-a3885ef8d00dfc8c8e5479c7b16e00443f1576e90487588173d4c31997d07c3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874937/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874937/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27502,27924,27925,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33680346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hori, Hiroaki</creatorcontrib><creatorcontrib>Itoh, Mariko</creatorcontrib><creatorcontrib>Matsui, Mie</creatorcontrib><creatorcontrib>Kamo, Toshiko</creatorcontrib><creatorcontrib>Saito, Takuya</creatorcontrib><creatorcontrib>Nishimatsu, Yoshiko</creatorcontrib><creatorcontrib>Kito, Satoshi</creatorcontrib><creatorcontrib>Kida, Satoshi</creatorcontrib><creatorcontrib>Kim, Yoshiharu</creatorcontrib><title>The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial</title><title>European journal of psychotraumatology</title><addtitle>Eur J Psychotraumatol</addtitle><description>Background: Currently, there is a paucity of pharmacological treatment options for posttraumatic stress disorder (PTSD), and the development of a novel pharmacotherapeutic approach has become a matter of great interest. Objective: We conducted a 12-week open-label clinical trial to examine the efficacy and safety of memantine, an N-methyl-D-aspartate receptor antagonist, in the treatment of civilian PTSD. Method: Thirteen adult patients with DSM-IV PTSD, all civilian women, were enrolled. They were monitored at an ambulatory care facility every week until 4 weeks and then every 4 weeks until 12 weeks. Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day and then titrated. Concomitant medications were essentially kept unchanged during the trial. The primary outcome was PTSD diagnosis and severity assessed with the Posttraumatic Diagnostic Scale (PDS). Results: Of the 13 cases, one dropped out and two were discarded due to the protocol deviation, and the analysis was done for the remaining 10. Mean PDS total scores decreased from 32.3 ± 9.7 at baseline to 12.2 ± 7.9 at endpoint, which was statistically significant with a large effect (paired t-test: p = .002, d = 1.35); intrusion, avoidance, hyperarousal symptoms were all significantly improved from baseline to endpoint. Six patients no longer fulfilled the diagnostic criteria of PTSD at endpoint. Some adverse, but not serious, effects possibly related to memantine were observed, including sleep problems, sleepiness, sedation, weight change and hypotension. Conclusions: Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated. Future randomized controlled trials are necessary to verify the efficacy and safety of memantine in the treatment of PTSD. * Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated.         * Its pre-post effect size is 1.35, almost comparable to that of trauma-focused CBT. * The finding accords with the results of recent studies of fear memory in rodents.</description><subject>Alzheimer's disease</subject><subject>Ambulatory care</subject><subject>Child &amp; adolescent psychiatry</subject><subject>Clinical</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>efficacy</subject><subject>Eficacia</subject><subject>Ensayo Clínico</subject><subject>FDA approval</subject><subject>Health psychology</subject><subject>Memantina</subject><subject>memantine</subject><subject>memoria</subject><subject>Memory</subject><subject>Mental health</subject><subject>Neurogenesis</subject><subject>Post traumatic stress disorder</subject><subject>Posttraumatic stress disorder (PTSD)</subject><subject>Psychotherapy</subject><subject>re-experiencing</subject><subject>Reexperimentación</subject><subject>safety</subject><subject>Seguridad</subject><subject>Trastorno de Estrés Postraumático (TEPT)</subject><subject>创伤后应激障碍 (PTSD); 美金刚; 记忆; 临床试验; 再体验; 有效性; 安全性</subject><issn>2000-8066</issn><issn>2000-8198</issn><issn>2000-8066</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNp9klFrFDEQxxdRbKn9CMqCL75cnSS7m8QHUYrVQsGX-hzmsrNtjmxyJrnKfXtzvWtpfRACSWZ-889k-DfNWwZnDBR85ACgmFZnHHgNqV4rzl40x7v4QsEwvHxyPmpOc17VGwx1Kf26ORJiUCC64bhx17fU0jQ5i3bbxqmdacZQXKDWhbbUZEmEZaZQdlnr7px3GNp1zKUk3MxYnG1zhXJuR5djGil9aisR1xQWHpfkq4RD_6Z5NaHPdHrYT5pfF9-uz38srn5-vzz_erWwvRzKAoVSPU1qBBgnq6yivpPayiUbCKDrxMQqRxo6JXulmBRjZwXTWo4grbDipLnc644RV2ad3IxpayI6cx-I6cZgqk17MoxZTjASt5J1TA5LjUIse47SIhecqtbnvdZ6s5xptHUKCf0z0eeZ4G7NTbwzUslOC1kFPhwEUvy9oVzM7LIl7zFQ3GTDO60BWK9YRd__g67iJoU6KsMHzbToJfSV6veUTTHnRNNjMwzMzhvmwRtm5w1z8Eate_f0J49VD06owJc94MIU04x_YvKjKbj1MU0Jg3XZiP-_8ReDqMgx</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Hori, Hiroaki</creator><creator>Itoh, Mariko</creator><creator>Matsui, Mie</creator><creator>Kamo, Toshiko</creator><creator>Saito, Takuya</creator><creator>Nishimatsu, Yoshiko</creator><creator>Kito, Satoshi</creator><creator>Kida, Satoshi</creator><creator>Kim, Yoshiharu</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial</title><author>Hori, Hiroaki ; Itoh, Mariko ; Matsui, Mie ; Kamo, Toshiko ; Saito, Takuya ; Nishimatsu, Yoshiko ; Kito, Satoshi ; Kida, Satoshi ; Kim, Yoshiharu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-a3885ef8d00dfc8c8e5479c7b16e00443f1576e90487588173d4c31997d07c3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer's disease</topic><topic>Ambulatory care</topic><topic>Child &amp; adolescent psychiatry</topic><topic>Clinical</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>efficacy</topic><topic>Eficacia</topic><topic>Ensayo Clínico</topic><topic>FDA approval</topic><topic>Health psychology</topic><topic>Memantina</topic><topic>memantine</topic><topic>memoria</topic><topic>Memory</topic><topic>Mental health</topic><topic>Neurogenesis</topic><topic>Post traumatic stress disorder</topic><topic>Posttraumatic stress disorder (PTSD)</topic><topic>Psychotherapy</topic><topic>re-experiencing</topic><topic>Reexperimentación</topic><topic>safety</topic><topic>Seguridad</topic><topic>Trastorno de Estrés Postraumático (TEPT)</topic><topic>创伤后应激障碍 (PTSD); 美金刚; 记忆; 临床试验; 再体验; 有效性; 安全性</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hori, Hiroaki</creatorcontrib><creatorcontrib>Itoh, Mariko</creatorcontrib><creatorcontrib>Matsui, Mie</creatorcontrib><creatorcontrib>Kamo, Toshiko</creatorcontrib><creatorcontrib>Saito, Takuya</creatorcontrib><creatorcontrib>Nishimatsu, Yoshiko</creatorcontrib><creatorcontrib>Kito, Satoshi</creatorcontrib><creatorcontrib>Kida, Satoshi</creatorcontrib><creatorcontrib>Kim, Yoshiharu</creatorcontrib><collection>Access via Taylor &amp; Francis (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>European journal of psychotraumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hori, Hiroaki</au><au>Itoh, Mariko</au><au>Matsui, Mie</au><au>Kamo, Toshiko</au><au>Saito, Takuya</au><au>Nishimatsu, Yoshiko</au><au>Kito, Satoshi</au><au>Kida, Satoshi</au><au>Kim, Yoshiharu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial</atitle><jtitle>European journal of psychotraumatology</jtitle><addtitle>Eur J Psychotraumatol</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>12</volume><issue>1</issue><spage>1859821</spage><epage>1859821</epage><pages>1859821-1859821</pages><issn>2000-8066</issn><issn>2000-8198</issn><eissn>2000-8066</eissn><abstract>Background: Currently, there is a paucity of pharmacological treatment options for posttraumatic stress disorder (PTSD), and the development of a novel pharmacotherapeutic approach has become a matter of great interest. Objective: We conducted a 12-week open-label clinical trial to examine the efficacy and safety of memantine, an N-methyl-D-aspartate receptor antagonist, in the treatment of civilian PTSD. Method: Thirteen adult patients with DSM-IV PTSD, all civilian women, were enrolled. They were monitored at an ambulatory care facility every week until 4 weeks and then every 4 weeks until 12 weeks. Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day and then titrated. Concomitant medications were essentially kept unchanged during the trial. The primary outcome was PTSD diagnosis and severity assessed with the Posttraumatic Diagnostic Scale (PDS). Results: Of the 13 cases, one dropped out and two were discarded due to the protocol deviation, and the analysis was done for the remaining 10. Mean PDS total scores decreased from 32.3 ± 9.7 at baseline to 12.2 ± 7.9 at endpoint, which was statistically significant with a large effect (paired t-test: p = .002, d = 1.35); intrusion, avoidance, hyperarousal symptoms were all significantly improved from baseline to endpoint. Six patients no longer fulfilled the diagnostic criteria of PTSD at endpoint. Some adverse, but not serious, effects possibly related to memantine were observed, including sleep problems, sleepiness, sedation, weight change and hypotension. Conclusions: Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated. Future randomized controlled trials are necessary to verify the efficacy and safety of memantine in the treatment of PTSD. * Memantine significantly reduced PTSD symptoms in civilian female PTSD patients and the drug was well tolerated.         * Its pre-post effect size is 1.35, almost comparable to that of trauma-focused CBT. * The finding accords with the results of recent studies of fear memory in rodents.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>33680346</pmid><doi>10.1080/20008198.2020.1859821</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2000-8066
ispartof European journal of psychotraumatology, 2021-01, Vol.12 (1), p.1859821-1859821
issn 2000-8066
2000-8198
2000-8066
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874937
source DOAJ Directory of Open Access Journals; Co-Action Open Access Journals; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Alzheimer's disease
Ambulatory care
Child & adolescent psychiatry
Clinical
clinical trial
Clinical trials
Drug therapy
efficacy
Eficacia
Ensayo Clínico
FDA approval
Health psychology
Memantina
memantine
memoria
Memory
Mental health
Neurogenesis
Post traumatic stress disorder
Posttraumatic stress disorder (PTSD)
Psychotherapy
re-experiencing
Reexperimentación
safety
Seguridad
Trastorno de Estrés Postraumático (TEPT)
创伤后应激障碍 (PTSD)
美金刚
记忆
临床试验
再体验
有效性
安全性
title The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20of%20memantine%20in%20the%20treatment%20of%20civilian%20posttraumatic%20stress%20disorder:%20an%20open-label%20trial&rft.jtitle=European%20journal%20of%20psychotraumatology&rft.au=Hori,%20Hiroaki&rft.date=2021-01-01&rft.volume=12&rft.issue=1&rft.spage=1859821&rft.epage=1859821&rft.pages=1859821-1859821&rft.issn=2000-8066&rft.eissn=2000-8066&rft_id=info:doi/10.1080/20008198.2020.1859821&rft_dat=%3Cproquest_pubme%3E2691935705%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2691935705&rft_id=info:pmid/33680346&rft_doaj_id=oai_doaj_org_article_11c2e0de2c714176b9a33b52a7ca232e&rfr_iscdi=true